ClinicalTrials.gg
CompletedNCT01307020DEX-TRA 02Updated Aug 12, 2013Results posted

Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain

A Phase 2 interventional study of Dexketoprofen Trometamol and Dexketoprofen Trometamol in Pain, sponsored by Menarini Group. Completed at 16 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-08-12.

Sponsored by Menarini Group · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
745
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing dexketoprofen in Pain — 1 open to participants now, 1 under way, none of them phase 3. dexketoprofen · Pain.

Enrollment
Largest of 10
745 · median 95
Started
2011
the only one that year
Phase 2
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
Menarini Group

Among the 10 studies testing dexketoprofen in Pain, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 2, and was the 1st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 10 studies testing dexketoprofen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexketoprofen

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dexketoprofen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the analgesic efficacy of Dexketoprofen Trometamol and Tramadol Hydrochloride given in combinations and the analgesic efficacy of each single component in comparison to placebo on moderate to severe pain following impacted third mandibular molar tooth extraction. Ibuprofen will be used as an active control to validate the pain model.

Read the detailed description

The aim of this study is to develop a combination of Dexketoprofen Trometamol (DKP.TRIS) and Tramadol Hydrochloride (TRAM.HCl) for the treatment of acute moderate to severe pain, based on the rationale that more than one drug is necessary in most patients suffering of acute and chronic pain, particularly of moderate to severe intensity.

DKP.TRIS and TRAM.HCl have different mechanisms of action, therefore their combination is expect to result in an additive or synergistic analgesia, thus allowing a decrease in the required doses of the individual agents, and consequently a reduced risk of adverse events In this study, patients who present moderate to severe pain after impacted third mandibular molar tooth extraction will be randomised to a total of 10 treatment arms including 4 combinations of DKP.TRIS + TRAM.HCl, the four corresponding single treatments, placebo and ibuprofen. Treatment administration will be followed by a 24-hour pain and analgesic effect assessment.

03

Conditions studied

  • Pain

Keywords

  • Moderate to severe pain
  • Postoperative pain
  • Analgesics
  • Dexketoprofen
  • Tramadol
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients meeting ALL the following criteria will be eligible for entry into the study:

  • Male or female patients aged 18 to 70 years old. Females participating in the study must be either: of non-, or willing to use a highly effective method.
  • Scheduled for outpatient surgical extraction -under local anaesthesia- of third mandibular molar teeth, with at least one of which is fully or partially impacted in the mandible requiring bone manipulation.
  • Normal physical examination or without abnormalities.

At randomisation (after surgery):

No intake of analgesics (including prescription and over the counter drugs) within 24h prior to the surgery.

  • No complication during the surgery, duration of surgery \< 1 hour and not requiring re-anaesthesia.
  • Patients experiencing pain of moderate or higher intensity in the first four hours after the end of surgery.

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to NSAIDs, opioids or acetyl salicylic acid.
  • History of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or angioneurotic oedema.
  • History of peptic ulcer, gastrointestinal disorders by NSAIDs, gastrointestinal bleeding or other active bleedings.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
745 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Ibuprofen

    Drug: Ibuprofen

  • Active comparator
    TRAM.HCl high dose

    Drug: Tramadol Hydrochloride

  • Active comparator
    TRAM.HCl low dose

    Drug: Tramadol Hydrochloride

  • Active comparator
    DKP-TRIS high dose

    Drug: Dexketoprofen Trometamol

  • Active comparator
    DKP-TRIS low dose

    Drug: Dexketoprofen Trometamol

  • Experimental
    DKP-TRIS low dose - TRAM.HCl low dose

    Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride

  • Experimental
    DKP-TRIS low dose - TRAM.HCl high dose

    Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride

  • Experimental
    DKP-TRIS high dose - TRAM.HCl low dose

    Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride

  • Experimental
    DKP-TRIS high dose - TRAM.HCl high dose

    Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride

Interventions

  • Dexketoprofen Trometamol low dose, oral film-coated table, once

  • Dexketoprofen Trometamol high dose, oral film-coated table, once

  • Tramadol Hydrochloride low dose, oral film-coated table, once

  • Tramadol Hydrochloride high dose, oral film-coated table, once

  • Ibuprofen 400 mg, oral film-coated table, once

  • DrugPlacebo

    Placebo, oral film-coated table, once

  • DrugDexketoprofen Trometamol + Tramadol Hydrochloride

    Drug pages: Dexketoprofen · Tramadol

    DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once

  • DrugDexketoprofen Trometamol + Tramadol Hydrochloride

    Drug pages: Dexketoprofen · Tramadol

    DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once

  • DrugDexketoprofen Trometamol + Tramadol Hydrochloride

    Drug pages: Dexketoprofen · Tramadol

    DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once

  • DrugDexketoprofen Trometamol + Tramadol Hydrochloride

    Drug pages: Dexketoprofen · Tramadol

    DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.

    Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %

    Time frame: 6 hours

Secondary outcomes

  1. Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.

    Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %

    Time frame: 4, 8 and 12 hours

  2. Percentage of Patients Using Rescue Medication at 6 Hours

    Percentage of patients using rescue medication at 6 hours post-dosing.

    Time frame: Baseline to 6 hours

07

Results

Posted Dec 10, 2012

Participant flow

First patient in (screening) 23 Feb 2011, last patient out 14 Oct 2011. At 16 study centres in 6 European countries (Germany, Italy, Hungary, Poland, Spain and United Kingdom).

Participant flow — Overall Study
MilestoneDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
Started61636361606159606162
Safety population61636361606159606162
Itt (>= 1 assessment post randomization)60626361606059596062
Completed61626260606158606162
Not completed0111001000
Withdrew: Lost to follow-up0011001000
Withdrew: Electronic data capture failure0100000000

Outcome measures

PrimaryPercentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %

Time frame:
6 hours
Reported as:
Number · percentage of patients
Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.
percentage of patientsDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.36.759.755.672.126.755.010.225.445.09.7
SecondaryPercentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is %

Time frame:
4, 8 and 12 hours
Reported as:
Number · percentage of patient
Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.
percentage of patientDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
at 4 hours post-dose63.372.665.178.740.065.011.923.756.76.5
at 8 hours post-dose21.748.444.454.116.731.76.820.333.36.5
at 12 hours post-dose11.735.528.637.710.013.35.115.325.06.5
SecondaryPercentage of Patients Using Rescue Medication at 6 Hours

Percentage of patients using rescue medication at 6 hours post-dosing.

Time frame:
Baseline to 6 hours
Reported as:
Number · percentage of patients
Percentage of Patients Using Rescue Medication at 6 Hours
percentage of patientsDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
Percentage of Patients Using Rescue Medication at 6 Hours66.746.839.737.765.053.369.564.448.372.6

Adverse events

Collected over 10 ± 3 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg—0/61 (0%)7/61 (11.5%)
DKP-TRIS 12.5mg - TRAM.HCl 75mg—0/63 (0%)9/63 (14.3%)
DKP-TRIS 25mg - TRAM.HCl 37.5mg—0/63 (0%)6/63 (9.5%)
DKP-TRIS 25mg - TRAM.HCl 75mg—0/61 (0%)10/61 (16.4%)
DKP-TRIS 12.5mg—0/60 (0%)2/60 (3.3%)
DKP-TRIS 25mg—0/61 (0%)4/61 (6.6%)
TRAM.HCl 37.5mg—0/59 (0%)5/59 (8.5%)
TRAM.HCl 75mg—1/60 (1.7%)14/60 (23.3%)
Ibuprofen 400mg—0/61 (0%)5/61 (8.2%)
Placebo—0/62 (0%)1/62 (1.6%)
Most frequent serious events
Most frequent serious events
EventDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
DizzinessNervous system disorders0/610/630/630/610/600/610/591/600/610/62
Most frequent other events
Most frequent other events
EventDKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlacebo
NauseaGastrointestinal disorders4/614/631/634/612/601/611/596/600/610/62
VomitingGastrointestinal disorders3/614/633/635/610/602/610/595/602/610/62
DizzinessNervous system disorders1/615/631/633/610/600/612/594/602/611/62
HeadacheNervous system disorders0/611/632/630/610/600/613/592/601/610/62
PyrexiaGeneral disorders3/610/630/633/610/602/611/593/601/610/62

Baseline characteristics

Age Continuous
Age Continuous(years)DKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlaceboTotal
Mean28.6 ± 7.6426.9 ± 7.6226.3 ± 7.3327.3 ± 7.5527.0 ± 9.8526.9 ± 6.9425.5 ± 7.1527.8 ± 7.9926.6 ± 6.4826.1 ± 6.6426.9 ± 7.56
Sex: Female, Male
Sex: Female, Male(Participants)DKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlaceboTotal
Female35393634364438284133364
Male26242727241721322029247
BMI
BMI(kg/m^2)DKP-TRIS 12.5mg - TRAM.HCl 37.5mgDKP-TRIS 12.5mg - TRAM.HCl 75mgDKP-TRIS 25mg - TRAM.HCl 37.5mgDKP-TRIS 25mg - TRAM.HCl 75mgDKP-TRIS 12.5mgDKP-TRIS 25mgTRAM.HCl 37.5mgTRAM.HCl 75mgIbuprofen 400mgPlaceboTotal
Mean23.7 ± 3.3924.1 ± 3.6923.0 ± 2.8723.2 ± 3.1923.6 ± 3.2023.5 ± 3.3023.0 ± 3.1924.2 ± 3.0822.4 ± 3.0422.7 ± 2.8023.3 ± 3.21
08

Study locations

16 sites
  • Klinik und Polickinik für Mund-Kiefer-Gesichtschirurgie/Plastische Operationen Greifswald
    Greifswald, Mecklenburg-Vorpommern 17475, Germany
  • Klinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Schleswig Holstein, Campus Kiel
    Kiel, Schleswig-Holstein 24105, Germany
  • Dr Tóth Bagi Zoltán Fogászati Rendeloje
    Budapest, 1052, Hungary
  • Centro di Farmacologia Clinica per la Sperimentazione dei Farmaci
    Pisa, 56126, Italy
  • Centro di Ricerche Cliniche di Verona Srl. Policlinico G.B.Rossi
    Verona, 37134, Italy
  • Gabinet Stomatologiczny Andrzej Wojtowicz AW Clinic
    Warsaw, Mazowieckie 00-852, Poland
  • Dental Service spólka jawna
    Warszawa, Mazowieckie 02-791, Poland
  • Hospital Médico Quirúrgico de Conxo
    Santiago de Compostela, A Coruña 15706, Spain
  • Facultad de Odontología. Departamento de Cirugía Bucal y Maxilofacial, University of Barcelona - Bellvitge Institute for Biomedical Research (IDIBELL)
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Universidad Complutense de Madrid
    Madrid, 28040, Spain
  • Departamento de Estomatología, Facultad de Odontología. Universidad de Sevilla
    Sevilla, 41009, Spain
  • Departament d'Estomatologia, Clínica Odontològica, Universidad de Valencia - Fundació Lluís Alcanyís
    Valencia, 046010, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • The School of Dentistry, College of Medical and Dental Sciences, University of Birmingham
    Birmingham, England B4 6 NN, United Kingdom
  • University Dental School Manchester
    Manchester, England M15 6FH, United Kingdom
  • University Dental Hospital
    Cardiff, Wales CF14 4 XY, United Kingdom
09

References and documents

Publications

  • Moore RA, Gay-Escoda C, Figueiredo R, Toth-Bagi Z, Dietrich T, Milleri S, Torres-Lagares D, Hill CM, Garcia-Garcia A, Coulthard P, Wojtowicz A, Matenko D, Penarrocha-Diago M, Cuadripani S, Piza-Vallespir B, Guerrero-Bayon C, Bertolotti M, Contini MP, Scartoni S, Nizzardo A, Capriati A, Maggi CA. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541. doi: 10.1186/s10194-015-0541-5. Epub 2015 Jun 27. PubMed 26123824 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 2, 2011
Start
Feb 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Dec 10, 2012
Last update
Aug 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01307020
Lead sponsor
Menarini Group
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Feb 2011
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Dec 10, 2012
Last update
Aug 12, 2013

Study contacts

Cosme Gay-Escoda, Professor
study chair · Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Barcelona - Bellvitge Institute for Biomedical Research (IDIBELL) 08907 Hospitalet de Llobregat, Barcelona (Spain)
R Andrew Moore, Professor
study chair · Pain Research & Nuffield Division of Anaesthesics, Department of Clinical Neurosciences, University of Oxford. The Churchill, Oxford OX3 7LJ (United Kingdom)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexketoprofen · Tramadol

Start the discussion